Dr. Armstrong Discusses Arches Trial In Prostate Cancer

Dr. Armstrong Discusses ARCHES Trial in Prostate Cancer

Dr. Armstrong Discusses Findings of ARCHES Trial in Prostate Cancer

Dr. Armstrong Discusses AR-V7 Testing in Prostate Cancer

Dr. Zhang on the ARCHES Trial in Prostate Cancer

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC

ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPC

Dr. Armstrong Discusses Hereditary Prostate Cancer

Andrew Armstrong, MD, on determining treatment of prostate cancer with DNA repair markers

Dr. Armstrong on the Utility of Pamiparib and Other PARP Inhibitors in Prostate Cancer

Update on ARCHES trial: implications for prostate cancer treatment

ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPC

Grand Rounds in Urology

Dr. Andrew Armstrong on Precision Medicine Approaches in Advanced Prostate Cancer

Update on overall survival in ARCHES trial

Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

ARCHES: enzalutamide plus ADT in mHSPC subgroups

Andrew Armstrong, MD, explains whether ARV-7 is predictive of response to taxanes in mPC patients

The Biology of Prostate Cancer

New Approaches to Metastatic Hormone Sensitive Prostate Cancer

Grand Rounds in Urology

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPC

Grand Rounds in Urology